Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now
Stake logo

CRISPR Therapeutics AG

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About CRSP

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Buy US stocks in Australia starting with CRSP. Open an account and start investing today!

Market Capitalisation

$5.14B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

903.4K

High today

$62.17

Low today

$60.41

Open price

$62.03

52-week high

$91.10

52-week low

$37.55


What is CRISPR Therapeutics and what do they do?

Gene editing was the stuff of science fiction not that long ago. But that's exactly the field that CRISPR Therapeutics spearheads nowadays. 

The company was founded in 2012 and is headquartered in Zug, Switzerland. They research means by which genomic DNA can be disrupted, deleted, corrected and inserted “to treat genetically-defined diseases and to engineer advanced cellular therapies” using CRISPR/Cas9-based therapeutics. Yes, of course it's complicated.

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, while Cas9 means CRISPR-associated protein 9. Suffice to say the technology allows for the precise alteration of specific sequences of genomic DNA. 

CRISPR Therapeutics’ most advanced programs currently target hemoglobinopathies including beta thalassemia and sickle cell disease. The company is also progressing a variety of cell therapy programs to treat haematological and solid tumour cancers.

Company Co-founder Dr. Emmanuelle Charpentier co-invented CRISPR/Cas9 with biochemist and geneticist Jennifer Doudna in 2011. They were both awarded the Nobel Prize in Chemistry in 2020.

Is CRISPR Therapeutics profitable?

Since going public in 2016, CRISPR Therapeutics’ earnings have been inconsistent. 

The company has achieved a positive net income for only two of the last eight financial years FY2019 with US$67m and FY2021 with US$378m. Earnings for all other years were negative.

CRISPR Therapeutics currently “have no products approved for commercial sale and have not generated any revenue from product sales.”

What kind of stock is CRSP?

CRSP is a biotechnology stock. The company specialises in gene editing and developing “transformative gene-based medicines for serious human diseases.”

Is CRISPR Therapeutics stock a buy?

Gene editing may or may not define the future of healthcare. Because of this, many investors see CRSP as a speculative play.

Investor sentiment has been negative for the past 15 months. The CRSP stock price plunged over 70% from its January 2021 high of over US$199 down to a low of US$50.54 in March 2022.

One of the biggest reasons for the drop is the company’s rising research and development costs. Another may be due to the company’s admission that they “have a history of recurring losses and expect to continue to incur losses for the foreseeable future.”

Does CRSP stock have a short interest?

Yes. As of 28 February 2022, CRISPR Therapeutics’ short interest totals 17.19% of all CRSP shares. This is up 4.93% from the previous month’s short interest.

When does CRSP report earnings?

CRISPR Therapeutics' most recent annual report was filed on 15 Feb 2022.

Since 2019, the company’s quarterly earnings have usually been reported in April, July and October or November.

Who owns the most CRSP stock?

Ark Investment Management is CRISPR Therapeutics biggest owner by far. It holds 11.79% of all CRSP stock.

CRSP’s other largest shareholders are institutional and include Nikko Asset Management (5.6%), Capital Research and Management Company (5.36%), SR One Capital Management (4.18%) and New Enterprise Associates (2.06%)

Co-founder Dr. Rodger Novak owns 0.74% of CRSP.

Ready to start your investing journey with Stake?

Open an account

CRSP FAQs

Yes, the Stake platform allows you to buy CRSP shares and over 12,000 stocks and ETFs across the ASX and Wall St.

One share of CRISPR Therapeutics AG is valued at $60.61.

The ticker symbol for CRISPR Therapeutics AG is CRSP.

To buy CRSP stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in CRSP

The CRISPR Therapeutics AG 52-week high stock price is $91.10.

The CRISPR Therapeutics AG 52-week low stock price is $37.55.

As of 19/06/2024 CRISPR Therapeutics AG has a market cap of $5.14B.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in CRSP
on Stake

Buy CRSP from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of CRSP from only US$10 with fractional shares

Get started
Canstar award phone
CRSP related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.